Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma
Cheoklong Ng(Shanghai Jiao Tong University), Jiwei Huang(Renji Hospital), Pei Dong(Sun Yat-sen University), Xiongjun Ye(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhankui Jia(First Affiliated Hospital of Zhengzhou University), Zejun Yan(Ningbo University Affiliated Hospital), Minfeng Chen(Jinan University), Wei Xiong(Sun Yat-sen University), Changwei Ji(Nanjing Drum Tower Hospital), Fan Li(Tongji Hospital), Tao Zhang, Jun Xiao(University of Science and Technology of China), Zhixian Yu(Wenzhou Medical University), Jianping Wu(Wannan Medical College), Le Qu(Nanjing General Hospital of Nanjing Military Command), Yige Bao(West China Hospital of Sichuan University), Chancan Li(Anhui Provincial Hospital), Guodong Zhu, Zhenyu Wang(Henan Provincial People's Hospital), Wei Xue(Kunming University), Chao Qin(Nanjing Medical University), Wen Cai(Second Affiliated Hospital of Zhejiang University), Gang Guo(Beijing Automotive Group (China)), Juping Zhao(Shanghai Jiao Tong University), Shangqian Wang(Jiangsu Province Hospital), Jitao Wu(Qingdao University), Xuedong Wei(Institute of Flight), Xiaoyi Hu(Fudan University), Zhiyang Huang(Fujian Medical University), Qi Tang(Peking University), Lei Zheng(First Hospital of Qinhuangdao), Cheng Peng(Shandong First Medical University), Taile Jing(Zhejiang University), Qing Yang(Capital Medical University)
Cited by 0
Related Papers
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
|Cancer Cell|2016|1.2k
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
|Chemical Society Reviews|2021|402
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
|Signal Transduction and Targeted Therapy|2023|364